Eli Lilly’s (LLY) Profit Potential with Drugs Mounjaro and Zepbound is Exceptional
Eli Lilly (LLY) could be a leading stock for 2024 as its diabetes drug Mounjaro and its weight loss drug Zepbound are now available.
Eli Lilly (LLY) could be a leading stock for 2024 as its diabetes drug Mounjaro and its weight loss drug Zepbound are now available.
Five Below (FIVE) is growing sales nicely (+14% last qtr) but profits are poor (-10%) as shoplifting is taking down profit margins.
2024 is looking like another strong year for Artificial Intelligence (AI) stocks. Here’s the ten stocks I like the best entering the New Year.
S&P Global (SPGI) had accelerated revenue growth across all divisions last quarter. And analysts see better things in store in 2024.
MongoDB (MDB) has been on a nice run higher the past year. But growth is expected to slow, and that could mean a lower valuation.
Cadence Design Systems (CDNS) is benefiting from generational trends like AI that are boosting demand for semiconductors.
The Trade Desk (TTD) continues ot deliver solid results in a suppressed ad market as people continue to move away from cable TV.
Lululemon (LULU) is having a busy holiday shopping season. But the stock’s recent run higher has zapped a lot of its upside.
DR Horton (DHI) stock has surged this month as investors anticipate lower interest rates in 2024, which should boost housing sales.
Merck (MRK) delivered good results last quarter. But this slow-growing company has a stock that’s been lackluster during 2023.
Shares of AMD (AMD) broke out after the company introduces its MI300 line of AI chipsets. But now shares of NVIDIA look better.
Generative AI is allowing loopholes that hackers can use to get to an organizations network. Zscaler (ZS) can help with that.